NEW YORK, Feb. 7 - Genzyme Molecular Oncology and Silico Insights will work together to characterize disease pathways and find new drug targets for breast cancer, Silico Insights said on Thursday.
The collaboration will apply data generated through Genzyme's gene expression database to Silico Insights' pathway analysis and interaction platform, I-Sight.
The two companies aim to characterize whole-genome expression from both breast cancer cells and normal breast tissue in the hopes of generating information that will lead to new therapeutic or diagnostic targets.
The Silico Insights platform allows researchers to identify the function of unknown genes and reveal relationships between disease-related genes. This ability helps to isolate pathways that are crucial to disease progression.
"The exciting part of our technology is that in addition to individual targets, the whole defective part of the pathway lights up, and the researcher can then select the best direction for drug targets," Silico Insights co-founder Christos Hatzis said in a statement.
Genzyme Molecular Oncology is a division of Genzyme. Its SAGE database is designed to provide rapid analysis of gene expression.
Silico Insights, based in Woburn, Mass., focuses on combining proteomics with informatics to investigate inflammatory diseases.